New hemophilia drug Mim8 tested for safe switch from current treatment
NCT ID NCT05878938
Summary
This study checked if it was safe for people with hemophilia A to switch from their current preventive medicine, emicizumab, to a new one called Mim8. It involved 61 adults and adolescents who had been on emicizumab. Participants received Mim8 via a pen injector weekly, every two weeks, or monthly for 6-12 months, and researchers tracked any side effects and how easy the new treatment was to use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
Vienna, 1090, Austria
-
AOU Careggi Firenze
Florence, Tuscany, 50134, Italy
-
Arthur Bloom Haemophilia Centre
Cardiff, CF14 4XW, United Kingdom
-
Augusta Univ/Childrens Hosp-GA
Augusta, Georgia, 30912, United States
-
Azienda Ospedaliera Santobono Pausilipon - U.S.D. Centro Regionale Pediatrico Malattie della Coagulazione
Naples, 80122, Italy
-
Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon
Naples, 80122, Italy
-
Belfast City Hospital
Belfast, BT9 78B, United Kingdom
-
Birmingham Children's Hospital
Birmingham, United Kingdom
-
Central Michigan University
Detroit, Michigan, 48201, United States
-
Charlotte Maxeke Johannesburg Academic Hospital
Parktown, Johannesburg, Gauteng, 2193, South Africa
-
Children's Hospital Los Angeles - Endocrinology
Los Angeles, California, 90027, United States
-
Cliniques universitaires Saint-Luc - Service Hématologie
Brussels, 1200, Belgium
-
Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
Hospices Civils de Lyon- Hopital Louis Pradel-1
Bron, 69500, France
-
Hospital Regional Universitario de Málaga
Málaga, 29010, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Kyung Hee University Hospital at Gangdong
Seoul, 05278, South Korea
-
McMaster University
Hamilton, Ontario, L8N 3Z5, Canada
-
Michigan State University
East Lansing, Michigan, 48824, United States
-
Nara Medical University Hospital_Pediatrics
Nara, 634-8522, Japan
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Penn State MS Hershey Med Ctr
Hershey, Pennsylvania, 17033-2360, United States
-
Royal Free Haemophilia Comprehensive Care Center
London, NW3 2QG, United Kingdom
-
Royal Free Haemophilia Comprehensive Care Centre
London, NW3 2QG, United Kingdom
-
Royal Hallamshire Hospital
Sheffield, S10 2JF, United Kingdom
-
Rush University Med. Cntr
Chicago, Illinois, 60612, United States
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
St Joseph's Hospital Foundation
Tampa, Florida, 33607, United States
-
UC Davis Medical Center
Sacramento, California, 95817, United States
-
UC Denver Hemoph & Thrombo Ctr
Aurora, Colorado, 80045, United States
-
Univ Hosp Cleveland Med Ctr
Cleveland, Ohio, 44106, United States
-
University of Iowa_Iowa City
Iowa City, Iowa, 52242, United States
-
Universitätsklinik für Innere Medizin V
Innsbruck, 6020, Austria
-
Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
Bonn, 53127, Germany
-
Vanderbilt U Med Ctr_Nashville
Nashville, Tennessee, 37212, United States
-
Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain
Berlin, 10249, Germany
Conditions
Explore the condition pages connected to this study.